|
Name |
2-[(3Z,7Z,12Z)-11,17-dihydroxy-1,4,8,12-tetramethyl-18-oxo-16-bicyclo[13.3.0]octadeca-3,7,12,16-tetraenyl]propyl acetate
|
Molecular Formula | C27H40O5 | |
IUPAC Name* |
2-[(3Z,7Z,12Z)-11,17-dihydroxy-1,4,8,12-tetramethyl-18-oxo-16-bicyclo[13.3.0]octadeca-3,7,12,16-tetraenyl]propyl acetate
|
|
SMILES |
C/C/1=C/CC/C(=C\CC2(C(C/C=C(\C(CC1)O)/C)C(=C(C2=O)O)C(C)COC(=O)C)C)/C
|
|
InChI |
InChI=1S/C27H40O5/c1-17-8-7-9-18(2)14-15-27(6)22(12-11-19(3)23(29)13-10-17)24(25(30)26(27)31)20(4)16-32-21(5)28/h8,11,14,20,22-23,29-30H,7,9-10,12-13,15-16H2,1-6H3/b17-8-,18-14-,19-11-
|
|
InChIKey |
VRGWBRLULZUWAJ-JFRLOPJASA-N
|
|
Synonyms |
FUSAPROLIFERIN
|
|
CAS | NA | |
PubChem CID | 101926417 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 444.6 | ALogp: | 3.5 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 83.8 | Aromatic Rings: | 2 |
Heavy Atoms: | 32 | QED Weighted: | 0.419 |
Caco-2 Permeability: | -4.737 | MDCK Permeability: | 0.00002420 |
Pgp-inhibitor: | 0.985 | Pgp-substrate: | 0.18 |
Human Intestinal Absorption (HIA): | 0.821 | 20% Bioavailability (F20%): | 0.97 |
30% Bioavailability (F30%): | 0.967 |
Blood-Brain-Barrier Penetration (BBB): | 0.952 | Plasma Protein Binding (PPB): | 92.82% |
Volume Distribution (VD): | 0.728 | Fu: | 7.94% |
CYP1A2-inhibitor: | 0.031 | CYP1A2-substrate: | 0.388 |
CYP2C19-inhibitor: | 0.169 | CYP2C19-substrate: | 0.842 |
CYP2C9-inhibitor: | 0.347 | CYP2C9-substrate: | 0.476 |
CYP2D6-inhibitor: | 0.019 | CYP2D6-substrate: | 0.395 |
CYP3A4-inhibitor: | 0.807 | CYP3A4-substrate: | 0.528 |
Clearance (CL): | 2.383 | Half-life (T1/2): | 0.7 |
hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.38 |
Drug-inuced Liver Injury (DILI): | 0.274 | AMES Toxicity: | 0.01 |
Rat Oral Acute Toxicity: | 0.311 | Maximum Recommended Daily Dose: | 0.89 |
Skin Sensitization: | 0.663 | Carcinogencity: | 0.837 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.011 |
Respiratory Toxicity: | 0.11 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005683 | 0.842 | D02CNR | 0.273 | ||||
ENC002974 | 0.802 | D0X4RS | 0.250 | ||||
ENC003560 | 0.802 | D09WYX | 0.243 | ||||
ENC001882 | 0.802 | D04GJN | 0.242 | ||||
ENC006130 | 0.644 | D02CJX | 0.238 | ||||
ENC005684 | 0.537 | D0V4WD | 0.232 | ||||
ENC005685 | 0.532 | D0V2JK | 0.231 | ||||
ENC004109 | 0.532 | D04ATM | 0.230 | ||||
ENC004376 | 0.491 | D01CKY | 0.230 | ||||
ENC003799 | 0.381 | D0T7ZQ | 0.228 |